Back to search

Article

Determinants of early antibody responses to COVID-19 mRNA vaccines in exposed and naive healthcare workers

2021-09-12

Abstract excerpt

<h4>Background</h4> Two doses of mRNA vaccination have shown >94% efficacy at preventing COVID-19 mostly in naive adults, but it is not clear if the second dose is needed to maximize effectiveness in those previously exposed to SARS-CoV-2 and what other factors affect responsiveness. <h4>Methods</h4> We measured IgA, IgG and IgM levels against SARS-CoV-2 spike (S) and nucleocapsid (N) antigens from the wild-type a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c7811407-6836-5282-9021-13eb9b51a72d
DOI
10.1101/2021.09.08.21263232
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Determinants of early antibody responses to COVID-19 mRNA vaccines in exposed and naive healthcare workersDOI 10.1101/2021.09.08.21263232
Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipientsSemantic proximity
Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and - experienced subjectsSemantic proximity
Evaluation of bivalent Omicron BA.1 booster vaccination after different priming regimens in healthcare workers (SWITCH ON): a randomized controlled trialSemantic proximity
Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine doseSemantic proximity
Serum anti-Spike antibody titers before and after heterologous booster with mRNA-1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccineSemantic proximity
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case seriesSemantic proximity
Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination StratagySemantic proximity
Titers and capacity of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: a single-blinded, randomized clinical trialSemantic proximity
Titers and Capacity of Neutralizing Antibodies Against SARS-CoV-2 Variants after Heterologous Booster Vaccination in Health Care Workers Primed with Two Doses of ChadOx1 nCov-19: A Single-Blinded, Randomized Clinical TrialSemantic proximity
Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workersSemantic proximity
Influence of past infection with SARS-CoV-2 on the response to the BioTech/Pfizer BNT162b2 mRNA vaccine in health care workers: kinetics and durability of the humoral responseSemantic proximity
Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variantsSemantic proximity
Select a neighboring publication to make it the new centre.